GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Persistent Facial Blanching after Botulinum Toxin Injection
    S. Karger AG ; 2022
    In:  Case Reports in Dermatology Vol. 14, No. 2 ( 2022-8-31), p. 253-257
    Details
    In: Case Reports in Dermatology, S. Karger AG, Vol. 14, No. 2 ( 2022-8-31), p. 253-257
    Abstract: We report the case of a 38-year-old male patient who presented with blanching of the face after strenuous exercise or physical exertion. The symptoms regressed in a relaxed state. Three years before presentation, he underwent botulinum toxin injections in the affected areas of the face. Facial blanching is a rare side effect of botulinum toxin injection. The postulated pathophysiology involves different transmitters mainly acetylcholine as well as co-transmitters implicated in vasodilation. Usually, facial blanching resolves shortly after waning of the botulinum toxin. However, in our case, the symptoms persisted for a longer time. Till date, therapy options for post-botulinum facial blanching are lacking, mainly due to the temporary aspect of the disease.
    Type of Medium: Online Resource
    ISSN: 1662-6567
    URL: Article
    DOI: 10.1159/000525937
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2022
    detail.hit.zdb_id: 2505300-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Immunotherapy of Melanoma
    S. Karger AG ; 2016
    In:  Oncology Research and Treatment Vol. 39, No. 6 ( 2016), p. 369-376
    Details
    In: Oncology Research and Treatment, S. Karger AG, Vol. 39, No. 6 ( 2016), p. 369-376
    Abstract: Arising from melanocytes in skin, mucosal membranes, eye, and meninges, melanoma is a tumor that has been associated with poor prognosis in advanced disease stages. Given the poor response to chemotherapy and radiation therapy, new treatment approaches with targeted therapy, immunotherapy, and adoptive T-cell therapy have revolutionized the standard of care for patients with advanced melanoma. This review provides a short overview of past, present, and future immunotherapeutic approaches and their limitations, with a focus on new combination agents in early clinical trials.
    Type of Medium: Online Resource
    ISSN: 2296-5270 , 2296-5262
    URL: Article
    DOI: 10.1159/000446716
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2016
    detail.hit.zdb_id: 2749752-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Lang anhaltendes Ansprechen auf die Behandlung mit Ipilimumab: Ein Argument gegen die Erhaltungstherapie?
    S. Karger AG ; 2015
    In:  Kompass Onkologie Vol. 2, No. 2 ( 2015), p. 72-75
    Details
    In: Kompass Onkologie, S. Karger AG, Vol. 2, No. 2 ( 2015), p. 72-75
    Abstract: Ipilimumab, ein monoklonaler CTLA-4-Antikörper, ist das erste Medikament, das das Gesamtüberleben bei metastasiertem Melanom verbessert hat. Allerdings sind noch Fragen zum Therapieregime offen, z.B. ob eine Erhaltungstherapie notwendig ist, um ein langfristiges Ansprechen zu erzielen. Wir stellen 3 Patienten mit metastasiertem Melanom vor, die nach Progression unter Chemotherapie mit Ipilimumab behandelt wurden. Bei all diesen Patienten führte Ipilimumab zu einer langfristigen Tumorkontrolle über mindestens 32 Monate. Bemerkenswert ist, dass bei allen Patienten eine schwere Autoimmuntoxizität auftrat und die Ipilimumab-Therapie nach 1 bzw. 2 Zyklen abgesetzt wurde. Die hier geschilderten Fälle belegen, dass ein langfristiges Ansprechen auf Ipilimumab ohne Erhaltungstherapie möglich ist.
    Type of Medium: Online Resource
    ISSN: 2296-5416 , 2296-5386
    URL: Article
    DOI: 10.1159/000440779
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2015
    detail.hit.zdb_id: 3050162-3
    detail.hit.zdb_id: 2754730-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Cellular and Molecular Mechanisms in the Induction Phase of Contact Sensitivity
    S. Karger AG ; 1995
    In:  International Archives of Allergy and Immunology Vol. 107, No. 1-3 ( 1995), p. 231-232
    Details
    In: International Archives of Allergy and Immunology, S. Karger AG, Vol. 107, No. 1-3 ( 1995), p. 231-232
    Type of Medium: Online Resource
    ISSN: 1018-2438 , 1423-0097
    URL: Article
    DOI: 10.1159/000236987
    RVK:
    XA 49650
    Language: English
    Publisher: S. Karger AG
    Publication Date: 1995
    detail.hit.zdb_id: 1482722-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Dermatology Life Quality Index and Side Effects after Topical Photodynamic Therapy of Actinic Keratosis
    S. Karger AG ; 2013
    In:  Dermatology Vol. 226, No. 3 ( 2013), p. 253-259
    Details
    In: Dermatology, S. Karger AG, Vol. 226, No. 3 ( 2013), p. 253-259
    Abstract: 〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Photodynamic therapy (PDT) is an excellent treatment option for actinic keratosis. However the side effects lead to an impairment of the patients' quality of life. 〈 b 〉 〈 i 〉 Objectives: 〈 /i 〉 〈 /b 〉 To evaluate the impact of PDT on patients' quality of life and to determine the frequency and intensity of side effects over the course of 4 weeks post PDT. 〈 b 〉 〈 i 〉 Patients and Methods: 〈 /i 〉 〈 /b 〉 22 patients with actinic keratosis in the face were included into this prospective study. Pain was measured using a visual analog scale immediately and 8 h after PDT. The Dermatology Life Quality Index (DLQI) was assessed at screening, after treatment as well as 2 and 4 weeks after PDT. The physician and patient evaluated the intensity of side effects during the treatment, 2 and 4 weeks post PDT. Additionally, the patient documented side effects daily from the 1st to the 14th day after PDT and on day 28 post PDT, using a diary. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 We observed a significant (p 〈 0.001) increase in the DLQI from 1.6 ± 1.7 prior to PDT to 7.3 ± 4.9 post PDT. The DLQI normalized in the following 4 weeks. Immediately and 8 h after PDT mean pain was 4.3 ± 2.5 and 2.3 ± 2.1. Side effects documented by the patients were erythema (100%), pain, burning, edema (90.9%), itching (86.4%), scaling (81.8%) and pustules (59.1%). No scar formation, hyper-/hypopigmentation or infections were observed. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 PDT has a significant temporary impact on patients' DLQI. Transitory side effects are common and show typical kinetics.
    Type of Medium: Online Resource
    ISSN: 1018-8665 , 1421-9832
    URL: Article
    DOI: 10.1159/000349992
    RVK:
    XA 37700
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2013
    detail.hit.zdb_id: 1482189-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Treatment with 5-Aminolaevulinic Acid Methylester Is Less Painful than Treatment with 5-Aminolaevulinic Acid Nanoemulsion in Topical Photodynamic Therapy for Actinic Keratosis
    S. Karger AG ; 2011
    In:  Dermatology Vol. 222, No. 4 ( 2011), p. 358-362
    Details
    In: Dermatology, S. Karger AG, Vol. 222, No. 4 ( 2011), p. 358-362
    Abstract: 〈 i 〉 Background: 〈 /i 〉 Topical photodynamic therapy (PDT) is an excellent treatment option for actinic keratosis (AK). Pain is one of the major adverse effects. 〈 i 〉 Objective: 〈 /i 〉 To compare the pain intensity during the extensive treatment of cosmetic units using 5-aminolaevulinic acid methylester (MAL) or 5-aminolaevulinic acid nanoemulsion (BF-200-ALA). 〈 i 〉 Methods: 〈 /i 〉 173 patients with 965 treated areas were enrolled in this retrospective monocentric study. All patients had multiple AKs and received an extensive treatment of the photodamaged area. 424 areas were treated with MAL and 541 with BF-200-ALA. Pain was rated using a standardized visual analogue scale (VAS). The number of PDT treatment interruptions was documented. 〈 i 〉 Results: 〈 /i 〉 PDT with MAL led to a lower mean VAS score (5.0 vs. 5.8), a lower number of treatment interruptions (13.2 vs. 19.9%) and a lower amount of patients experiencing severe pain (25.0 vs. 36.0%) compared to PDT with BF-200-ALA. 〈 i 〉 Conclusion: 〈 /i 〉 Our data shows that PDT using MAL is less painful than PDT using BF-200-ALA resulting in a significantly lower mean VAS score (p 〈 0.001), significantly fewer patients experiencing severe pain (p 〈 0.001) and a significantly (p 〈 0.05) lower number of treatment interruptions. Differences in selectivity for tumour cells and transport of ALA in peripheral neurons may play a role.
    Type of Medium: Online Resource
    ISSN: 1018-8665 , 1421-9832
    URL: Article
    DOI: 10.1159/000329025
    RVK:
    XA 37700
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2011
    detail.hit.zdb_id: 1482189-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    A Case of Extensive Grover’s Disease in a Patient with a History of Multiple Non-Melanoma Skin Cancers
    S. Karger AG ; 2021
    In:  Case Reports in Dermatology Vol. 13, No. 3 ( 2021-12-7), p. 553-557
    Details
    In: Case Reports in Dermatology, S. Karger AG, Vol. 13, No. 3 ( 2021-12-7), p. 553-557
    Abstract: We report on a 69-year-old man who presented with itching and erythematous papules on his torso and extremities, which were resistant to topical therapy with antibiotics and steroids. Physical examination revealed multiple erythematous papules on his back, neckline, and lower extremities. The lesions had appeared 4 years earlier and usually worsened with heat or extensive sweating. Histopathology of previous skin biopsies had shown multiple cutaneous squamous cell carcinomas or was non-conclusive. Thus, a re-biopsy was performed, revealing acanthosis and focal acantholytic dyskeratosis. These clinical and anamnestic findings lead to the diagnosis of extensive Grover’s disease (GD). Oral therapy with isotretinoin 30-mg QD led to the regression of the skin lesions. Topical adapalene, as well as topical corticosteroids, were later prescribed for maintenance therapy.
    Type of Medium: Online Resource
    ISSN: 1662-6567
    URL: Article
    DOI: 10.1159/000519168
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2021
    detail.hit.zdb_id: 2505300-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    T Cell Receptor Mimic Peptidesand Their Potential Application in T-Cell-Mediated Diseas e
    S. Karger AG ; 2000
    In:  International Archives of Allergy and Immunology Vol. 123, No. 4 ( 2000), p. 275-281
    Details
    In: International Archives of Allergy and Immunology, S. Karger AG, Vol. 123, No. 4 ( 2000), p. 275-281
    Abstract: 〈 i 〉 Background: 〈 /i 〉 A T cell receptor (TCR) peptide was designed that mimics the intramembranous amino acid sequence of the TCR chain. Prior studies had shown that this mimic peptide would inhibit TCR signaling. This study was designed to investigate the use of this mimic peptide for the treatment of T-cell-mediated skin diseases. 〈 i 〉 Methods: 〈 /i 〉 Synthesized mimic peptides were first tested for their T-cell-inhibitory effect in proliferation assays. Afterwards, mimic peptides were applied to murine ear skin prior to application of a contact allergen and tested for their inhibitory effect in the model of murine allergic contact sensitivity. The effect of epicutaneous treatment with the peptide was also tested on patients with T-cell-mediated skin disease. 〈 i 〉 Results: 〈 /i 〉 Mimic peptide potently inhibited proliferation of CD4+ and CD8+ T cells when added to allogeneic proliferation assays using dendritic cells as antigen-presenting cells (APCs). Suppression of the proliferative capacity could be overcome by addition of an anti-CD3 monoclonal antibody. When applied to murine ear skin prior to application of a contact allergen, mimic peptide efficiently blocked ear swelling responses in mice. In humans, application of mimic peptide for the treatment of various diseases resulted in amelioration or even cure in patients suffering from atopic dermatitis, psoriasis or lichen planus. 〈 i 〉 Conclusions: 〈 /i 〉 TCR mimic peptide efficiently abrogates T-cell-mediated immune responses in mice and man in vitro and in vivo. The potential immunosuppressive effect of the drug is discussed.
    Type of Medium: Online Resource
    ISSN: 1018-2438 , 1423-0097
    URL: Article
    DOI: 10.1159/000053639
    RVK:
    XA 49650
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2000
    detail.hit.zdb_id: 1482722-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Long-Lasting Responses under Treatment with Ipilimumab: An Argument against Maintenance Therapy?
    S. Karger AG ; 2015
    In:  Dermatology Vol. 230, No. 1 ( 2015), p. 8-10
    Details
    In: Dermatology, S. Karger AG, Vol. 230, No. 1 ( 2015), p. 8-10
    Abstract: Ipilimumab, a monoclonal CTLA-4 antibody, was the first drug improving overall survival in patients with metastatic melanoma. However, there are still unanswered questions concerning therapeutic regimes, e.g. if maintenance therapy is needed to achieve long-term response. We present three patients with metastatic melanoma who received ipilimumab after progression under chemotherapy. In all of these patients ipilimumab led to a long-term tumor control of at least 32 months. Interestingly, all of them developed severe autoimmune toxicity and ipilimumab treatment was discontinued after 1 respectively 2 cycles. The present cases demonstrate that a long-term response to ipilimumab can be achieved without maintenance therapy.
    Type of Medium: Online Resource
    ISSN: 1018-8665 , 1421-9832
    URL: Article
    DOI: 10.1159/000365078
    RVK:
    XA 37700
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2015
    detail.hit.zdb_id: 1482189-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Linear IgA Bullous Dermatosis Secondary to Infliximab Therapy in a Patient with Ulcerative Colitis
    S. Karger AG ; 2015
    In:  Dermatology Vol. 231, No. 2 ( 2015), p. 112-115
    Details
    In: Dermatology, S. Karger AG, Vol. 231, No. 2 ( 2015), p. 112-115
    Abstract: Linear IgA bullous disease (LABD) is a rare vesiculobullous autoimmune skin disorder whose etiology and pathogenesis are not completely understood. Its occurrence has been related to malignancies, inflammatory diseases and several drugs. This report describes a 49-year-old Caucasian male with a 14-year history of ulcerative colitis who received infliximab to treat the refractory course of his bowel disease. During induction therapy with infliximab, he developed LABD. Treatment with infliximab was discontinued, and the skin lesions were successfully treated with oral steroids and dapsone. Considering the close chronological relation between administration of the tumor necrosis factor-α inhibitor and onset of the skin disease, we hypothesize that this is the first reported case of infliximab-induced LABD. Similar to psoriasis, it may represent a ‘paradoxical' autoimmune reaction triggered by anti-tumor necrosis factor-α therapy.
    Type of Medium: Online Resource
    ISSN: 1018-8665 , 1421-9832
    URL: Article
    DOI: 10.1159/000431172
    RVK:
    XA 37700
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2015
    detail.hit.zdb_id: 1482189-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...